Efficacy and Safety of CRT, Durvalumab and Surgery for SST
Status:
Not yet recruiting
Trial end date:
2030-08-31
Target enrollment:
Participant gender:
Summary
The safety and efficacy of multimodality treatment of pre- and post-operative durvalumab
therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor (SST) and
durvalumab maintenance therapy after chemoradiotherapy for unresectable SST
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Center Hospital East
Collaborators:
AstraZeneca Japan Agency for Medical Research and Development Japan Clinical Oncology Group